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Although gastrointestinal cancers are frequently associated with chronic inflammation, the underlying
molecular links have not been comprehensively deciphered. Using loss- and gain-of-function mice in
a colitis-associated cancer model, we establish here a link comprising the gp130/Stat3 transcription factor
signaling axis. Mutagen-induced tumor growth and multiplicity are reduced following intestinal epithelial
cell (IEC)-specific Stat3 ablation, while its hyperactivation promotes tumor incidence and growth.
Conversely, IEC-specific Stat3 deficiency enhances susceptibility to chemically induced epithelial damage
and subsequent mucosal inflammation, while excessive Stat3 activation confers resistance to colitis. Stat3
has the capacity to mediate IL-6- and IL-11-dependent IEC survival and to promote proliferation through
G1 and G2/M cell-cycle progression as the common tumor cell-autonomous mechanism that bridges chronic
inflammation to tumor promotion.
INTRODUCTION
Persistent and aberrant activation of various members of the
signal transducer and activator of transcription (STAT) family is
a recurrent and unifying molecular feature of many human
malignancies of hematological and epithelial origin (Levy and
Darnell, 2002; Yu and Jove, 2004). Among the seven STAT
proteins, hyperactivation of STAT3 has been shown to promote
tumor growth directly by tumor-autonomous mechanisms as
well as indirectly by regulating the antitumor response of the
tumor-associated stroma and the immune system. Thus,
STAT3 plays a pivotal role in the regulation of transcriptional
programs that are essential prerequisites for carcinogenesis
(Hanahan and Weinberg, 2000), including those regulating cell
survival, proliferation, angiogenesis, and tumor-induced immu-
nosuppressive functions (Yu et al., 2007). Meanwhile, many of
the major signal transduction pathways activated in cancer
and initiated by the receptor tyrosine kinases for epidermal,
platelet-derived, and vascular endothelial growth factors, by
cytokines of the interleukin-6 (IL-6) and IL-10 families, or by non-
receptor tyrosine kinases converge on STAT3. Indeed, aberrant
activation of STAT3 in human cancers is invariably associated
with the presence of constitutive activating mutations in
upstream (receptor) tyrosine kinases or tumor-associated over-
supply of the aforementioned ligands, while such mutations in
the STAT3 gene have not been identified. These observations
SIGNIFICANCE
Aberrant Stat3 activation is a recurrent finding in many tumors, but the mechanism (or mechanisms) by which Stat3 links
inflammation to cancer remains elusive. Using genetically modified mouse strains that harbor mutations in the Stat3
signaling cascade, we here identify in an inflammation-associated colon cancer model a dual role for mucosal Stat3 in medi-
ating an anti-inflammatory cytoprotective effect as well as in enhancing tumor growth. Thus, upon stimulation by IL-6 family
cytokines, which are produced by inflammatory and other tumor-associated cells, Stat3 acts as a unifying cancer cell-
autonomous transcription factor node that simultaneously enables survival of mutagenized cells and subsequent tumor
promotion in situ.
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latent cytoplasmic STAT3 to form dimers that are able to bind
to DNA and to regulate transcription. Likewise, epigenetic
impairment mutations in genes encoding negative regulators of
STAT3 signaling, including the tyrosine phosphatase PTPRT
and suppressor of cytokine signaling 3 (SOCS3), result in persis-
tent STAT3 activation and associated tumorigenesis (He et al.,
2003; Zhang et al., 2007).
Gene deletion studies in mice have identified a nonredundant
function for Stat3 in transducing signals from the common IL-6
cytokine family receptor b subunit gp130 (Heinrich et al., 2003).
In order for signaling to be initiated, gp130 requires either homo-
dimerization, which is induced upon binding of IL-6 or IL-11 to
their respective receptor a subunits, or heterodimerization with
structurally related receptor b subunits in response to the remain-
ing ligands that comprise the IL-6 cytokine family (Heinrich et al.,
2003). In either case, b subunit dimerization triggers activation of
associated Janus kinases and subsequent phosphorylation of
cytoplasmic tyrosine (Y) residues, whereby the four membrane-
distal tyrosines engage Stat3 and to a lesser extent Stat1. Mean-
while, ligand-dependent gp130 phosphorylation of the most
membrane-proximal residue Y757 (Y759 in human gp130) results
in engagement of the tyrosine phosphatase Shp2 and activation
of the downstream Ras/Erk and PI3K/Akt signaling cascades, as
well as providing the binding site for the regulatory protein Socs3,
which serves to limit gp130 signaling.
A causal link between inflammation and cancer is well
accepted (Karin and Greten, 2005; Mantovani et al., 2008), and
several recent studies in genetically modified mice have helped
to dissect and characterize some of the underlying molecular
events. One major regulatory pathway linking inflammation and
cancer comprises IKKb-dependent activation of NF-kB (Karin
and Greten, 2005). Elevated NF-kB activity in premalignant
epithelial cells suppresses apoptosis, thereby promoting their
survival and subsequent capacity to form tumors. Meanwhile,
engagement of the same pathway in tumor-associated inflam-
matory cells initiates transcription of proinflammatory cytokines,
which in turn stimulate the proliferation of tumor and stromal
cells to further fuel tumor growth (Karin and Greten, 2005). One
of the NF-kB-dependent inflammatory growth factors thought
to be essential for inflammation-associated carcinogenesis is
IL-6 (Naugler and Karin, 2008). Indeed, in a colitis-associated
cancer (CAC) model wherein chronic inflammation triggered
through administration of the luminal toxin dextran sodium
sulfate (DSS) reveals the mutagenic effect of prior exposure to
the colonotropic mutagen azoxymethane (AOM), we recently
proposed that myeloid-specific deletion of IKKb suppresses
tumor incidence and size at least in part through reduced
myeloid-specific Il6 transcription (Greten et al., 2004). T lympho-
cytes furthermore regulate tumor growth in the CAC model via
a TGF-b-dependent mechanism that limits IL-6 trans-signaling,
because its inhibition by administration of either neutralizing
IL-6 receptor a chain antibodies or soluble gp130-Fc suppresses
enterocyte-specific Stat3 activation and proliferation and
culminates in reduced tumor incidence (Becker et al., 2004).
Recent circumstantial evidence has further promoted the
concept that the IL-6/gp130/Stat3 signaling axis may also
provide an autocrine and paracrine amplification loop in lung
adenocarcinoma (Gao et al., 2007), multiple myeloma (Catlett-
Falcone et al., 1999), and Ras-transformed cancer cells (Ancrile
et al., 2007). Thus, Stat3 is likely to serve as the signaling node
that integrates tumor cell-autonomous signals with tumorigenic
cues indirectly provided through the immune system.
Here we genetically manipulated Stat3 expression and activa-
tion in the intestinal epithelium using various gain-of-function
and loss-of-function mouse models to define and dissect the
causal role played by Stat3 during CAC-induced colonic tumor-
igenesis. We define a function for Stat3 in the intestinal epithe-
lium, where it mediates resistance to DSS-induced epithelial
damage and promotes tumorigenesis. Therefore, the capacity
of Stat3 to suppress apoptosis and stimulate proliferation not
only facilitates colitis-associated wound healing but at the
same time also promotes mutagen-induced tumor growth.
These observations demonstrate that, in addition to IKKb-
dependent NF-kB activation, Stat3 may comprise a central
node and checkpoint during inflammation-associated carcino-
genesis and is therefore likely to represent a promising target
for therapeutic intervention.
RESULTS
Intestinal Stat3 Activity Modulates Colitis-Associated
Tumorigenesis
To directly examine the effect of Stat3 expression in colonic
epithelium during the process of CAC, we generated compound
mutant mice that lacked Stat3 specifically in all epithelial cell line-
ages of the intestine. These mice carried a homozygous muta-
tion encompassing a loxP-flanked exon 21 of the Stat3 gene
(Stat3flox) (Takeda et al., 1998) and simultaneously expressed
Cre recombinase under the control of the intestine-specific villin
gene promoter (villin-Cre) (Madison et al., 2002). Since villin is
ubiquitously expressed throughout the epithelial layer of the
intestine, including the presumed stem cell compartment, we
confirmed the absence of full-length Stat3 protein in the resulting
homozygous Stat3DIEC mice by immunoblot analysis of isolated
intestinal epithelial cells (IECs) from their small and large intes-
tines, respectively (see Figure S1 available online). IEC-specific
Stat3 deficiency had no effect on the development and function
of the intestine in adult mice, and the baseline rate of proliferation
and apoptotic index were indistinguishable under steady-state
conditions between unchallenged Stat3flox and Stat3DIEC mice
(Figure S1). Furthermore, Stat3DIEC mice were healthy and fertile
and did not display any overt phenotype when routinely bred for
up to 4 months of age.
Next, we exposed Stat3DIEC mice to the CAC challenge and
found that they were almost completely protected from the
development of AOM-induced tubular adenomas (Figure 1A),
while 100% of Stat3-proficient Stat3flox mice (8 of 8) developed
adenomatous lesions in the distal colon (Figures 1A and 1C).
Furthermore, the few polypoid lesions protruding into the lumen
that developed in the small proportion of Stat3DIEC mice (2 of 8)
(Figure 1D) were markedly reduced in size (Figure 1B). To explore
a possible dose-response relationship between Stat3 activation
and CAC-dependent tumorigenesis, we took advantage of
the gp130Y757F mouse model, in which IL-6 and IL-11 trigger
global Stat3 hyperactivation, including in the colonic epithelium
(Figure S2) (Jenkins et al., 2005; Tebbutt et al., 2002). As
opposed to our findings in Stat3DIEC mice, we observed
92 Cancer Cell 15, 91–102, February 3, 2009 ª2009 Elsevier Inc.
Cancer Cell
Stat3 Links Inflammation to Colon Cancerincreased multiplicity of frequency and size of AOM + DSS-
induced tumors in gp130Y757F mice (Figures 1A, 1B, and 1E)
when compared to wild-type mice. To assess the consequence
of manipulating Stat3 expression or activation on tumor cell
proliferation, we determined BrdU incorporation in tumor
epithelia. In agreement with a profound effect on tumor size,
we observed a significant reduction of the BrdU proliferation
index in Stat3DIEC mice, which was elevated by 25% in
gp130Y757F mice when compared to Stat3flox mice (Figure 1F).
By contrast, TUNEL analysis revealed a reciprocal increase in
the apoptotic response of the colonic mucosa in Stat3DIEC
mice when compared to Stat3flox and gp130Y757F mice (Figures
1G–1I). Collectively, the results obtained with the direct Stat3
loss-of-function (Stat3DIEC) model and the indirect gp130-
dependent Stat3 gain-of-function (gp130Y757F) model implicate
a dose-response relationship between epithelial Stat3 activation
and colonic tumor incidence as well as tumor growth in the CAC
model.
Interestingly, we found that despite the smaller number and
size of tumors in Stat3DIEC mice, these lesions were consis-
tently associated with more severe colonic mucosal inflamma-
tion and greater tissue damage than observed in Stat3flox mice
(Figures 2B–2F). However, it remained unclear whether the
exaggerated inflammatory response in Stat3DIEC mice was
compounded by the initial mutagenic challenge. Therefore,
we exposed Stat3DIEC mice to three cycles of DSS without
the initial AOM challenge and found that this treatment also
resulted in extensive ulceration and epithelial damage scores
that were significantly higher in Stat3DIEC compared to Stat3flox
control mice (Figure S3). Collectively, these observations
suggest a strong protective role for Stat3 in IECs during chronic
colitis, and they argue against the possibility that tumor devel-
opment is suppressed in Stat3DIEC mice because of less
pronounced mucosal inflammation.
AOM induces missense mutations in exon 3 of Catnb that lead
to stabilization and nuclear translocation of b-catenin, thereby
activating the Wnt/b-catenin pathway (Greten et al., 2004). Acti-
vation of this signaling pathway triggers formation of colonic flat
low-grade intraepithelial neoplasias, which then further progress
into tubular adenomas in wild-type and Stat3flox mice. Instead of
developing these advanced tubular tumors, CAC-challenged
Stat3DIEC mice displayed multifocal flat low-grade intraepithelial
neoplasias in active colitis (Figure 2G and 2H). To confirm that
the latter lesions indeed genetically represented tumor precur-
sors, we applied laser capture microdissection (LCM) to isolate
DNA from epithelial cells from intraepithelial neoplastic lesions
as well as from the few CAC-induced advanced tubular
adenomas from Stat3DIEC mice. We consistently identified acti-
vating mutations in exon 3 of Catnb in all lesions of Stat3DIEC
mice examined (data not shown) and also confirmed deletion
of exon 21 of Stat3 (data not shown). Furthermore, similar muta-
tions in Catnb were found in DNA isolated by LCM from Stat3flox
tubular adenomas, while the majority of tubular adenomas iso-
lated from gp130Y757F mice showed nuclear localization of acti-
vated b-catenin (Figure S4), consistent with AOM-induced acti-
vating Catnb mutations. Collectively, we conclude from these
observations that epithelial depletion of Stat3 blocks early tumor
development and that the extent of Stat3 activation modifies







Figure 1. Stat3 Is Essential for Colitis-Associated Tumor Develop-
ment
(A and B) Tumor incidence (A) and mean tumor size (B) in Stat3flox, Stat3DIEC,
and gp130Y757F mice after completion of the colitis-associated cancer (CAC)
challenge at day 84.
(C–E) Hematoxylin and eosin (H&E)-stained sections of colons from mice at the
end of the CAC challenge (day 84) showing representative adenomatous
polyps protruding into the colonic lumen in Stat3flox mice (C), Stat3DIEC mice
(D), and gp130Y757F mice (E). Scale bars = 200 mm.
(F) BrdU proliferation index of epithelial cells in polyps protruding into the
lumen of Stat3flox, Stat3DIEC, and gp130Y757F mice.
(G–I) Assessment of apoptosis by TUNEL staining of tumors from Stat3flox (G),
Stat3DIEC (H), and gp130Y757F mice (I) on day 84 of the CAC challenge. Scale
bars = 100 mm. A magnified view of the boxed area from the Stat3DIEC mouse
in (H)confirms thatTUNEL-positivesignalsoriginate primarily fromepithelialcells.
Note thatCAC-dependent tumor incidence ingp130Y757F animals was compared
to that in wild-type littermate controls, which showed tumor incidence and size
comparable to Stat3flox mice and were therefore omitted from the graphs. Data
are mean ± SEM. Differences between groups were analyzed by one-way
ANOVA.
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Tumor Promotion
We have shown previously that ablation of IKKb in either entero-
cytes or myeloid cells affects apoptosis and proliferation during
the early stages of tumor promotion in the CAC model, thereby
reducing tumor incidence and size, respectively (Greten et al.,
2004). We thus focused our analysis on these time points to eluci-
date the molecular mechanisms by which Stat3 confers its
tumorigenic properties. To examine whether IEC-specific dele-
tion of Stat3 renders enterocytes more susceptible to apoptosis
at the beginning of the CAC protocol, we injected Stat3flox and
Stat3DIEC mice with AOM and sacrificed them 3 days after initia-
tion of DSS treatment, which corresponds to day 8 of the CAC
regimen (Figure 3A). Immunohistochemical analysis revealed
enterocyte-specific nuclear localization of the tyrosine-phos-
phorylated (activated) form of Stat3 (p-Stat3) in Stat3flox mice
(Figure 3B), and this signal was completely absent from IECs in
colons ofStat3DIEC mice (Figure 3C), which was further confirmed
by immunoblot analysis of purified epithelial cells (Figure 3H). The
lack of Stat3 activation in Stat3DIEC mice coincided with the pres-
ence of extended areas of epithelial apoptosis in the mucosa
as visualized by immunohistochemical staining for active cas-
pase-3 (Figures 3D and 3E) and by TUNEL (Figures 3F and
3G). Biochemical analysis confirmed pronounced activation
(cleavage) of caspase-9 and thus an increased apoptotic
response in isolated Stat3-deficient colonocytes (Figure 3H)
when compared to IECs from Stat3flox mice. Meanwhile, in
Stat3-proficientStat3flox mice, we observed induction of the anti-
apoptotic proteins Bcl-XL and survivin, as well as upregulation of
the ATP-dependent chaperone protein Hsp70. In contrast, colo-
nocytes derived from challenged Stat3DIEC mice failed to reveal





Figure 2. Increased Epithelial Damage and
Infiltration of Inflammatory Cells in Stat3DIEC
Mice after Completion of the CACChallenge
(A) Schematic representation of the CAC model.
(B and C) Histological damage (B) and number of
ulcers (C) in Stat3flox, Stat3DIEC, and gp130Y757F
mice analyzed on day 84 of the CAC model. Data
are mean ± SEM. n = 8.
(D–F) Representative H&E-stained sections demon-
strating varying degrees of inflammation in mice of
the indicated genotypes. Scale bars = 200 mm.
(G and H) Representative H&E-stained section of
multifocal flat low-grade intraepithelial neoplasia
(indicated by dashed line) frequently found in
Stat3DIEC mice at the end of the CAC challenge (G)
as well as a larger magnification of this tumor
precursor (H). Scale bars = 100 mm.
that the bcl-x, survivin, and Hspa1a
(encoding Hsp70) genes are transcrip-
tionally induced by Stat3 (Yu and Jove,
2004). Interestingly, we found constitutive
expression of Bcl-2 and Stat3-inde-
pendent induction of Mcl-1 (Figure 3H),
despite the fact that these two anti-
apoptotic proteins are also encoded by
presumed Stat3 target genes (Yu and
Jove, 2004). Similarly, we observed constitutive expression of
the proapoptotic proteins Bax and Bak, while the induction of
Fas/CD95 also occurred independently of Stat3. Collectively,
these results suggest that impaired induction of Bcl-XL, survivin,
and Hsp70 protein expression, rather than differential regulation
of Bcl-2, Mcl-1, Bak, and Bax, may account for the increased rate
of apoptosis observed in AOM + DSS-challengedStat3DIEC mice.
Stat3 Stimulates Regeneration and Proliferation
during Colitis
DSS-induced apoptosis leads to an epithelial barrier defect and
translocation of bacterial commensals, which initiate an inflam-
matory cascade. Once DSS administration is suspended,
colonic epithelium can regenerate and inflammation resolves.
This mucosal regeneration stage represents a wound-healing
reaction during which hyperproliferation of epithelial cells is stim-
ulated by proinflammatory cytokines and growth factors that are
secreted by recruited inflammatory cells. Thus, we hypothesized
that the increased initial apoptosis in Stat3DIEC mice should indi-
rectly induce a more severe form of acute colitis. Indeed, when
we monitored body weights during the first cycle of DSS-
induced acute colitis after AOM administration, Stat3DIEC mice
lost significantly more weight than Stat3flox mice (Figure 4A).
More importantly, Stat3flox mice rapidly regained normal body
weight a few days after removal of DSS from the drinking water,
while Stat3DIEC mice exhibited a delayed recovery. This was
further supported by histopathological analysis of mice at day
15 of the CAC regimen, 5 days after termination of DSS adminis-
tration. We found that colons of Stat3DIEC mice exhibited wide-
spread damage to the colonic mucosa, with extensive epithelial
denudation and larger numbers of ulcerations compared to the
partially preserved epithelial structures observed in Stat3flox
94 Cancer Cell 15, 91–102, February 3, 2009 ª2009 Elsevier Inc.
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colonic enterocytes (Figures 4F and 4G). Meanwhile, the exten-
sive hyperinflammatory response in Stat3DIEC mice associated
with the increased epithelial damage was accompanied by
elevated expression of mRNAs encoding IL-1b, IL-6, IL-11,
Cox-2, ICAM-1, and IL-10 in the colonic mucosa of these
mice, whereas no differences were observed in TNFa and
IFN-g expression (Figure 4I). However, despite a more profound
inflammatory response and the associated increase in growth-
stimulating signals in Stat3DIEC mice, BrdU incorporation studies
revealed impaired proliferation of their colonic enterocytes as
compared to colonic crypts of Stat3flox mice (Figure 4J).
The increased inflammatory reaction and wound-healing
defect observed in Stat3DIEC mice was reminiscent of our
previous findings in gp130DSTAT mice (Tebbutt et al., 2002) and
therefore strongly suggested that the lost capacity of epithelial
cells to activate Stat3 in response to IL-6 family cytokines
was primarily responsible for DSS-induced mucosal damage.
This conclusion is supported by the converse finding that
gp130Y757F mutant mice, which carry a knockin mutation to
confer ligand-dependent Stat3 and Stat1 hyperactivation, remain
largely protected against colonic epithelial injury (Tebbutt et al.,
2002). In order to genetically confirm that this effect is selectively
conferred by Stat3 rather than Stat1 hyperactivation, we geneti-
cally reduced the global pool of either Stat3 or Stat1 available
for activation in gp130Y757F mice. Indeed, the protective effect
observed in gp130Y757F mice was partially reverted in the cor-
responding gp130Y757F/Stat3+/ mice but was retained in
gp130Y757F/Stat1+/ mice (Figure S5). Having established
that the clinical protection against DSS-induced colitis of
gp130Y757F mice is largely dependent on Stat3 hyperactivation,
we examined whether gp130Y757F mice would also display
a phenotype reciprocal to that of Stat3DIEC mice with respect to
the proliferative mucosal wound-healing reaction. In line with
the decreased mucosal susceptibility of gp130Y757F mice to
DSS, we found that BrdU incorporation after DSS challenge
was significantly higher in IECs of gp130Y757F mutant mice than
in IECs of wild-type mice (Figures 5A–5C).
Since impaired expression of Stat3 in myeloid cells results in
enhanced susceptibility to colitis (Takeda et al., 1999) and since
gp130Y757F mice exhibit systemic gp130-dependent Stat3
hyperactivation, we next wished to determine whether the
protective effect observed in gp130Y757F mutants is independent
of the anti-inflammatory response elicited in macrophages of
these mice (El Kasmi et al., 2006). We therefore performed recip-
rocal bone-marrow reconstitution experiments in gp130Y757F
and wild-type mice 2 months prior to DSS challenge and
observed that the presence of mutant hematopoietic cells
did not reduce susceptibility of wild-type hosts to the DSS chal-
lenge (Figure S6). On the other hand, gp130Y757F mutant hosts
remained more resistant to DSS than wild-type hosts, irrespec-
tive of the genotypes of their hematopoietic cells. These clinical
observations matched differential BrdU incorporation results,
which were elevated in the resistant gp130Y757F mutant hosts
(Figure 5C). Collectively, these results argue in favor of an IEC-
autonomous mechanism by which Stat3-dependent hyperprolif-
eration mediates the protective effect against DSS-induced
colitis. This conclusion is also supported by our observation
that IEC-specific overexpression of a mutant form of constitu-
tively active Lgp130 (Stuhlmann-Laeisz et al., 2006) confers


















Figure 3. Loss of Stat3 in Intestinal Epithelial Cells Sensitizes Enter-
ocytes to Apoptosis Early after AOM and DSS Administration
(A) Schematic representation of the initial steps of the CAC challenge that
results in maximal apoptotic response on day 8 of the CAC regimen.
(B–G) Immunohistochemical analysis of phospho-Stat3 (B and C), cleaved
caspase-3 (D and E), and TUNEL staining (F and G) of colons from Stat3flox
mice (B, D, and F) andStat3DIEC mice (C, E, and G). Insets in (B) and (C) demon-
strate nuclear localization of phospho-Stat3 in Stat3flox mice (B) that is absent
from enterocytes in Stat3DIEC mice (C). Scale bars = 100 mm.
(H) Immunoblot analysis for the indicated proteins in lysates prepared from
isolated enterocytes from Stat3flox and Stat3DIEC mice at day 8 of the CAC
challenge.Cancer Cell 15, 91–102, February 3, 2009 ª2009 Elsevier Inc. 95
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signaling, promotes tumorigenesis in a model of inflammation-
associated gastric cancer (Ernst et al., 2008), while IL-6 has
been proposed to play this role in the CAC model (Becker
et al., 2004; see also the accompanying paper by Grivennikov
et al. [2009] in this issue of Cancer Cell). We therefore examined
genetically which of these cytokines triggers the colitis-protec-
tive proliferative phenotype in gp130Y757F mice. Whereas
double-mutant gp130Y757F/Il6/ and gp130Y757F/Il11ra/
mice exhibited a hyperproliferative phenotype similar to
gp130Y757F mice (Figure 5D), only the corresponding triple-
compound gp130Y757F/Il11ra//Il6/ mutant mice, which
simultaneously lack IL-6 and IL-11 signaling, showed a signifi-
cant reduction in BrdU-positive IECs after DSS challenge (Fig-
ure 5D). These results suggest redundant activity for the latter
two cytokines in eliciting a gp130/Stat3-dependent proliferative
mucosal response, which is therefore likely to also promote
inflammation-associated tumor progression in the colon.
Hyperproliferation in gp130Y757F Mice Is Associated
with Cell-Cycle Alterations during G1 and G2/M Phase
We next aimed to identify genes that are induced at the height of
the Stat3-mediated proliferative response. Therefore, we iso-
lated RNA from IECs of gp130Y757F and wild-type mice at day
12 of the CAC model (Figure 6A) and performed quantitative
PCR analysis for cell-cycle genes encoding the late G1 to
G1/S phase proteins cyclin D1, cyclin D2, cyclin E, and c-Myc;
the G2/M phase proteins cdc2 and cyclin B1; and the cyclin-
dependent kinase (Cdk) inhibitor p21cip. Although basal expres-
sion of cyclins D2 and E was comparable between wild-type and
gp130Y757F mice, we found that AOM + DSS treatment induced











Figure 4. Stat3DIECMice DevelopMore Severe Acute Ulcerative Colitis during the CACRegimen and Show ImpairedMucosal Wound Healing
(A) Changes in body weight of Stat3flox and Stat3DIEC mice during the first cycle of acute DSS-induced colitis. Five days after AOM treatment, mice were admin-
istered 3.5% DSS in the drinking water for 5 days, followed by a 5 day recovery phase on normal drinking water. All mice were sacrificed and analyzed on day 15 of
the CAC regimen. Data are mean ± SEM. nR 7; **p < 0.01, ***p < 0.001 by t test.
(B and C) Histological damage (B) and number of ulcers (C) in Stat3flox and Stat3DIEC mice analyzed at day 15 of the CAC model. Data are mean ± SEM. nR 7;
***p < 0.001 by t test.
(D–H) Representative H&E-stained sections (D and E) and immunohistochemical analysis of phospho-Stat3 (F–H) of colons from Stat3flox mice (D and F) and
Stat3DIEC mice (E and H) at day 15 of the CAC challenge or in an unchallenged Stat3flox mouse (G). Scale bars = 100 mm.
(I) Relative expression levels of cytokine mRNAs isolated from whole colonic mucosa of Stat3flox and Stat3DIEC mice at day 15 of the CAC model and analyzed by
real-time PCR. Data are mean ± SEM. nR 3.
(J) BrdU proliferation index in colonic enterocytes of Stat3flox and Stat3DIEC mice before and at day 15 of the CAC challenge. Data are mean ± SEM. nR 7; *p <
0.05 by t test.
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type mice. This suggested a stimulatory effect of Stat3 on G1
and G2/M transition of the cell cycle, and this observation was
consistent with more profound downregulation of the Cdk in-
hibitor p21cip in IECs from gp130Y757F mice. To confirm that
these alterations conferred increased cyclin-dependent kinase
activity, we performed immunocomplex kinase assays for
cdk4/cyclin D and cdc2/cyclin B using GST-Rb and histone H1
as substrates, respectively. Although we observed elevated
activity for both kinase complexes in IECs of AOM + DSS-treated
wild-type mice, this effect was stronger in IECs prepared from
challenged gp130Y757F mice (Figure 6C). In contrast, the activity
of these kinase complexes as well as the expression of cyclin D1
and c-Myc was blunted in IECs from AOM + DSS-treated
Stat3DIEC mice, while p21cip expression was elevated (Figures
6C and 6D), further supporting our findings that these effects
are indeed dependent on the extent of Stat3 activation. Mean-
while, we found strong nuclear expression of cyclin B1 in the
epithelial cell components of the AOM-induced tumors in wild-
type and gp130Y757F mice, which was almost completely absent
from the polyp precursors observed in Stat3DIEC mice (Figures
7A and 7B; data not shown). Conversely, intraepithelial
neoplastic lesions inStat3DIEC mice showed a significantly higher
number of IEC nuclei that stained positive for the M phase
cell-cycle marker phosphohistone H3 (Figures 7C and 7D).
Collectively, these findings strongly suggest a mitotic arrest in
Stat3-deficient, AOM-mutagenized IECs that is likely to provide
a molecular explanation for the pronounced growth arrest of
polyp precursors in Stat3DIEC mice.
Finally, we wished to establish whether the antiapoptotic
response observed in IECs of Stat3-proficient mice during early
phases of the DSS challenge (see Figure 3H) persisted through
the stages of maximal wound healing observed 2 days after
the DSS challenge, corresponding to day 12 of the CAC regimen
(Figure 6A). Indeed, we observed that expression of genes
encoding Bcl-XL, survivin, and Hsp70 remained elevated in
gp130Y757F compared to control mice (Figure 6B; data not
shown). Compared to wild-type mice, we also noted in
gp130Y757F mice a more pronounced induction of RegIIIb/Pap
mRNA (Figure 6B). Meanwhile, expression of RegIIIb/PAP
protein and survivin was markedly decreased in Stat3DIEC
mice (Figures 7F and 7H), while epithelial cells comprising the
CAC-dependent tumors in Stat3-proficient mice displayed
strong expression of these proteins (Figures 7E and 7G). Collec-
tively, these results strongly support the notion that the Stat3-
associated antiapoptotic, prosurvival effects not only are
present within preneoplastic cells during early tumor promotion
in the CAC model but remain important for tumor epithelia.
DISCUSSION
A causal link between chronic inflammation and the develop-
ment of cancer has long been recognized, and substantial insight
into the underlying molecular mechanisms has been obtained in
recent years. A large body of evidence suggests that Stat3, along
with NF-kB, is one of the few key regulatory signaling molecules
whose aberrant activation is invariably associated with inflam-
mation and cancer, yet genetic evidence confirming such
a role for Stat3 is still outstanding. With the advent of tissue-
specific gene manipulation, it has become clear that Stat3 plays
nonredundant roles in shaping the inflammatory response
elicited by both proinflammatory stimuli belonging predomi-
nantly to the gp130 family of cytokines as well as anti-inflamma-
tory signals elicited by IL-10-related cytokines. In turn, this
balance has been postulated to modulate the tumor microenvi-
ronment, including the provision to subvert antitumor immune
response. Meanwhile, emerging evidence suggests a central
role for Stat3 in providing a transcriptional node for cancer
cell-autonomous initiation of a tumor-promoting gene signature
associated with proliferation, survival, and angiogenesis.
A B
Figure 5. IL-6 and IL-11 Induce Intestinal Epithelial Cell Hyperprolif-
eration in gp130Y757F Mice during the Healing Phase of Acute Colitis
(A and B) BrdU incorporation in colonic crypts of wild-type (A) and gp130Y757F
mice (B) after one cycle of DSS-induced colitis, 1 day after termination of DSS
administration. Scale bars = 100 mm.
(C) Relative change in BrdU incorporation in colonic crypts of gp130Y757F mice
or respective bone marrow-transplanted mice compared to wild-type mice
after one cycle of DSS-induced colitis (WT > > Y757F indicates wild-type
bone marrow transplanted into gp130Y757F recipient mice).
(D) Relative change in BrdU incorporation in colonic crypts of gp130Y757F/
Il11ra/, gp130Y757F/Il6/, and gp130Y757F/Il11ra//Il6/ compound
mutants compared to single-mutant gp130Y757F mice after one cycle of
DSS-induced colitis.
BrdU-positive cells were only determined in well-oriented crypts. Data are
averages of 15 crypts/mouse, n R 5. Data are mean ± SEM. Differences
between genotypes were analyzed by one-way ANOVA.
Cancer Cell 15, 91–102, February 3, 2009 ª2009 Elsevier Inc. 97
Cancer Cell
Stat3 Links Inflammation to Colon CancerAlthough a number of growth factors as well as cell-intrinsic
(epi)mutations have been associated with aberrant Stat3 activa-
tion during metaplastic transformation (Ernst et al., 2008; Miyat-
suka et al., 2006) and in cancers of epithelial origin, the IL-6
family cytokines have recently been proposed to provide one
of the missing links between inflammation and cancer (Naugler
and Karin, 2008). Using a tissue-specific gain- and loss-of-func-
tion approach, we have provided direct genetic evidence that the
gp130/Stat3 signaling axis indeed comprises a nonredundant
regulatory component within the microenvironment of inflamma-
tion-associated tumors. Significantly, Stat3 stimulates both cell
survival and proliferation (most likely alongside tumor angiogen-
esis), which explains the profound tumor-suppressive pheno-
type observed in Stat3DIEC mice. This is in contrast to the role
played by epithelial NF-kB in the CAC model, where we previ-
ously found that IEC-specific ablation of IKKb profoundly
suppresses tumor incidence without affecting tumor size (Greten
et al., 2004). This phenotype results from excessive apoptosis
during early tumor promotion, with an associated loss of muta-
genized cells in which AOM induces the tumor-initiating insult.
Indeed, suppression of the survival gene bcl-x, which is a molec-
ular target for both NF-kB and Stat3, is a common observation
during the early mucosal response to the DSS insult in lesions
of IKKbDIEC and Stat3DIEC mice. Furthermore, this also coincides
in Stat3DIEC mice with impaired induction of survivin and Hsp70.
In agreement, administration of IKKb-specific inhibitors to wild-
type mice during DSS-induced colitis is associated with reduced
Stat3 activation and Hsp70 expression and impaired mucosal
healing (Eckmann et al., 2008). In contrast to the observation
presented here, where IEC-specific Stat3 ablation suppressed
epithelial proliferation through a cell-autonomous mechanism
in normal (i.e., in the acute DSS-induced colitis model) as well
as in mutagenized mucosa (i.e., in the CAC model), such an
effect was only observed following genetic blockage of NF-kB
activation in myeloid cells of IKKbDmye mice, but not in entero-
cytes of their IKKbDIEC counterparts. We attributed these findings
to the reduced production of paracrine-acting, tumor-promoting
gp130 family cytokines by inflammation-associated, IKKb-
deficient macrophages and neutrophils. These observations




Figure 6. Stat3 Controls Expression of G1/S and G2/M Regulators
(A) Schematic representation of the initial steps of the CAC challenge that results in maximal proliferative response on day 12 of the CAC regimen.
(B) Expression of cell-cycle and apoptosis regulators in isolated intestinal epithelial cells (IECs) of wild-type (WT; black bars) and gp130Y757F mice (white bars)
before or at day 12 of the CAC challenge. Relative expression levels of mRNAs were determined by real-time PCR. Data are mean ± SEM.
(C) Immunoblot analysis of cyclin D1 and immunocomplex kinase assay of cdk4 and cdc2 prepared from isolated IECs of WT, gp130Y757F, and Stat3DIEC mice
before or at day 12 of the CAC challenge.
(D) Relative expression levels of mRNAs encoding c-Myc and p21 in Stat3flox (black bars) and Stat3DIEC mice (gray bars) at day 12 of the CAC challenge. Data are
mean ± SEM.
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Stat3 Links Inflammation to Colon Cancerevidence that myeloid NF-kB and IEC Stat3 provide the func-
tional link by which inflammatory cells in the tumor microenviron-
ment stimulate proliferation and promote tumor growth. Unlike
the proposed function for NF-kB in myeloid cells, analogous
Stat3 ablation in Mx-Cre/Stat3flox (Alonzi et al., 2004) or LysM-
Cre/Stat3flox mice (Takeda et al., 1999) increased susceptibility
to spontaneous colitis by virtue of disrupting the anti-inflamma-
tory activity transduced by IL-10. In findings complementary to
our observations here, elevated bacterial load in Il10-deficient
mice frequently culminates in the development of colorectal
cancer (Berg et al., 1996).
Our data support recent circumstantial evidence implicating
the gp130/Stat3 signaling cascade in inflammation-associated
cancer of the skin (Chan et al., 2004) and the gastrointestinal
tract. We previously demonstrated that the initiation of sponta-
neously arising metaplastic gastric cancer in gp130Y757F mice
is refractory to antimicrobial treatment (Judd et al., 2006) and
genetic reduction of Stat3 expression (Jenkins et al., 2005), while
established lesions depend on continuous Stat3 activation (Ernst
et al., 2008). Similarly, IEC-specific deletion of the negative
feedback regulator Socs3 enables excessive Stat3 activation
during the course of the CAC challenge and is associated with
increased tumor numbers (Rigby et al., 2007). Meanwhile, in
the same model, inhibition of IL-6-dependent trans-signaling
reduces Stat3 phosphorylation and mucosal proliferation
(Becker et al., 2004). Our results here extend these observations
by providing functional evidence that, among the gp130-
activating cytokines, at least IL-6- and IL-11-dependent Stat3
activation promotes CAC development by regulating the G1
and G2/M phases of the cell cycle. Thus, Stat3 activation
provides one of the cell-autonomous mechanisms that function-
ally link inflammation-associated cytokines in the tumor micro-
environment to the tumorigenic expansion of latent cancer cells.
Here we identify a number of aberrantly expressed effector
proteins, some of which have been validated by other studies
as bona fide Stat3 target genes and whose aberrant expression
coincides with excessive phospho-Stat3 in various human
cancers. It is therefore highly likely that, for instance, Hsp70,
RegIIIb/PAP, survivin, cyclin B1, cdc2, c-Myc, and cyclin D1
are also intimately involved in mediating survival and proliferation
of IECs in the CAC model (Figure 8). Indeed, Hsp70 is an impor-
tant antiapoptotic factor for IECs (Sikora and Grzesiuk, 2007)
and confers protection to colonic epithelia against DSS-induced
damage (Tanaka et al., 2007). Furthermore, IFN-gand IL-6 induce
expression of the C-type lectin RegIIIb/PAP, which is upregulated
in DSS-induced colitis in mice as well as in human inflammatory
bowel disease (te Velde et al., 2007) and in 60% of colon cancers
(Macadam et al., 2000). Significantly, Stat3-mediated signaling in
response to the IL-10 family cytokine IL-22 protects against
experimental colitis (Sugimoto et al., 2008). This observation
correlates with enhanced expression of RegIIIb/PAP along with
several mucins (Zheng et al., 2008), which are also upregulated
in untreated gp130Y757F mice (data not shown). The bifunctional
role of the small inhibitor of apoptosis (IAP) family protein survivin
in counteracting apoptosis as well as controlling mitogenic
progression (Altieri, 2008) is likely to provide a functional explana-
tion for some of our observations on cell-cycle protein expres-
sion. In untransformed cells, survivin is selectively expressed
during the G2/M transition, localizes to mitotic spindle microtu-
bules (Li et al., 1998), and is phosphorylated by physical associ-









Figure 7. Loss of Stat3 Induces Mitotic Arrest in Preneoplastic
Lesions
(A–H) Immunohistochemical analysis of cyclin B1 (A and B), phosphohistone H3
(C and D), survivin (E and F), and RegIIIb/PAP (G and H) in tumors from Stat3flox
mice (A, C, E, and G) and intraepithelial neoplasias found inStat3DIEC mice (B, D,
F, and H) at the end of the CAC model on day 84. Scale bars = 100 mm.
Figure 8. Schematic Overview of gp130/Stat3-Mediated Effects on
Tumor Promotion
During CAC, both IL-6 and IL-11 induce gp130-mediated Stat3 activation.
Stat3 comprises a central node responsible for cell survival and proliferation
by regulating various downstream targets that ultimately favor accumulation
and promotion of mutated cells.
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Stat3 Links Inflammation to Colon Cancersurvivin knockdown induces a G2/M arrest in human colorectal
cancer cells (Rodel et al., 2005). In preneoplastic lesions of
Stat3DIEC mice, impaired survivin expression may also account
for the increase in phosphohistone H3-positive cells indicating
a mitotic arrest. Finally, cucurbitacin I-mediated inhibition of
Stat3 (Blaskovich et al., 2003) induces cell-cycle arrest at the
G2/M transition in cell lines derived from either laryngeal squa-
mous cell carcinoma or glioblastoma multiforme, which, similar
to our observations in lesions from Stat3DIEC mice, is associated
with the downregulation of cyclin B1 and cdc2 (Liu et al., 2008; Su
et al., 2008). However, it remains to be established whether Stat3
can regulate cyclin B1 in IECs directly, as recently suggested in
other cell types (Snyder et al., 2008).
The high prevalence of activating Catnb mutations in AOM-
induced tubular adenomas irrespective of the compounding
mutations in the gp130/Stat3 signaling cascade observed here
suggests a putative role for Stat3 in executing a strong modifier
function for colorectal tumors carrying activating mutations in
the canonical Wnt pathway. This function requires the supply
of gp130 family ligands from infiltrating inflammatory cells, which
promote intestinal polyposis in the ApcMin mouse model (Rakoff-
Nahoum and Medzhitov, 2007) where aberrant Wnt signaling
results from stochastic loss-of-heterozygosity mutations of the
tumor suppressor gene Apc in the epithelial stem cell compart-
ment. Thus, tumor load is reduced in ApcMin/Il6/ compound
mutant mice (Baltgalvis et al., 2008), while their ApcMin/
gp130Y757F counterparts show increased tumor multiplicity
(T.J.P. and M.E., unpublished data). Although the exact mecha-
nism remains to be elucidated, it is conceivable that the canon-
ical Wnt and Stat3 pathways intersect on common molecular
targets including c-myc and cyclin D1 to induce transcription
above the threshold required for cell-cycle progression. On the
other hand, the failure to eliminate cyclin D1 due to sustained
Stat3 activation may bypass the DNA replication checkpoint
response (Shields et al., 2008), which is likely to impact aberrant
chromosome segregation triggered in the absence of functional
Apc protein (Dikovskaya et al., 2007).
Several compounds targeting Stat3 have shown promising
results in cultured cells and preclinical models (Darnell, 2005;
Groner et al., 2008). Although excessive interference with
systemic Stat3 activation is likely to curtail the beneficial anti-
inflammatory response of macrophages, with the potential
consequence of further fueling gastrointestinal inflammation,
Stat3-dependent cancers are generally highly sensitive to small
reductions in Stat3 activity. The resulting therapeutic window
may therefore allow systemic delivery of Stat3 inhibitors to
indirectly ‘‘target’’ Stat3-addicted tumors with beneficial selec-
tivity (Ernst et al., 2008) while still enhancing T cell-mediated anti-
tumor activities (Yu et al., 2007). In the context of inflammation-
associated gastrointestinal cancers, the validity and efficacy of
such strategies need to be assessed against, or in combination
with, inhibitors of the myeloid NF-kB/IL-6 signaling axis as well
as those directed against IL-11.
EXPERIMENTAL PROCEDURES
Mice and CAC Model
To delete Stat3 in IECs, we crossed Stat3lox/lox mice (termed Stat3flox) (Takeda
et al., 1998) to villin-Cre transgenic mice (Madison et al., 2002), which were
backcrossed for four generations on an FVB background before intercrossing
to generate compound mutant villin-Cre/Stat3lox/lox mice (termed Stat3DIEC).
Mutant gp130Y757F/Y757F mice (termed gp130Y757F), as well as their compound
derivatives gp130Y757F/Il6/, gp130Y757F/Il11ra/, gp130Y757F/Stat3+/, and
gp130Y757F/Stat1+/ mice, were all on a C57BL/6 3 129Sv background and
have been described previously (Ernst et al., 2008). The CAC model was per-
formed essentially as described previously (Greten et al., 2004) using 10 mg/kg
azoxymethane (AOM; Sigma-Aldrich) and 3.5% dextran sulfate sodium (DSS;
MP Biomedicals). Histological assessment of colitis was performed as
described previously (Eckmann et al., 2008; Greten et al., 2004). In all experi-
ments, littermate controls were used to assure comparison of mice on the
same genetic background. All procedures were approved by the Ludwig
Institute for Cancer Research, Department of Surgery Committee and the
Regierung von Oberbayern, respectively.
Determination of Proliferation, Migration Rates, and Apoptosis
Mice were injected intraperitoneally with 100 mg/kg BrdU (Sigma) 1.5 hr prior
to sacrifice, and paraffin sections were stained using anti-BrdU antibody
(Amersham Biosciences RPN201). For determination of migration rates,
BrdU-injected mice were sacrificed 48 hr after injection. For each analysis,
BrdU-positive cells were scored in 12 full crypts from three animals of each
genotype. Apoptosis was determined by TUNEL assay using an ApoAlert
DNA Fragmentation Assay Kit (BD Clontech).
Protein Analysis and Immunohistochemistry
Isolation of enterocytes, immunoblot analysis, and immunocomplex kinase
assay were essentially performed as described previously (Greten et al.,
2004). Paraffin sections (3.5 mm) were stained using standard immunohisto-
chemical procedures. Antibodies used were anti-Stat3 (SC-482), anti-Stat1
(SC-346, Santa Cruz), anti-phospho-Stat3 (9145), anti-cleaved caspase-3
(9661), anti-caspase-9 (9504), anti-survivin (2808), anti-phosphohistone H3
(9701, Cell Signaling), anti-HSP70 (SPA-810, Stressgen), anti-Bcl-2 (610539),
anti-Bcl-XL (556499), anti-Bax (554106, BD Pharmingen), anti-b-catenin
(UBI 6734), anti-RegIIIb/PAP (Algul et al., 2007), anti-Mcl-1 (SC-819), anti-
Bak (SC-832), anti-Fas (SC-1024), anti-cyclin D1 (SC-718), anti-c-Myc
(SC-788), anti-cyclin B1 (SC-752, Santa Cruz), and anti-b-actin (A4700, Sigma).
RNA Analysis
Total RNA was extracted from isolated enterocytes using an RNeasy Mini Kit
(QIAGEN). SuperScript II Reverse Transcriptase (Invitrogen) was used for
synthesis of cDNA. Real-time PCR analysis using Power SYBR Green PCR
Master Mix (Applied Biosystems) was performed on a StepOne Plus Real-
Time PCR System (Applied Biosystems). Primer sequences are listed in
Supplemental Experimental Procedures.
Statistical Analysis
Data are expressed as mean ± SEM. Differences were analyzed by one-way
ANOVA or Student’s t test. p% 0.05 was considered significant.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
six figures and can be found with this article online at http://www.cancercell.
org/supplemental/S1535-6108(09)00003-8.
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